Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma: A Phase II, Multi-center, Open-label Study

NCT02328261 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT02328261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02328261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma: A Phase II, Multi-center, Open-label Study
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2014
Completion date
April 30, 2017
Enrollment
66 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma